Depo-Provera has been linked to meningioma, a tumor that forms along the membranes surrounding the brain and spinal cord. Across the country, women who developed these tumors have filed lawsuits against the makers of the injection. They argue that the makers of this contraceptive injection failed to alert women to the danger of meningioma, leaving patients without the information needed to weigh that risk for themselves. This argument, known as failure to warn, forms the foundation of much of the Depo-Provera litigation.
What Failure to Warn Means in a Defective Medication Claim
Some defective drug claims are based on a flaw in how a product was designed or an error introduced while it was being manufactured. However, a pharmaceutical product may be considered legally defective when its maker fails to provide adequate warnings about a known or foreseeable danger, even if the drug itself was manufactured correctly.
Companies carry a duty to disclose serious risks on their labels and to keep that information current as new safety data emerges. When a manufacturer learns of a hazard but does not pass that warning along to patients and physicians, the law may hold it responsible for the harm that follows.
Did Depo-Provera’s Manufacturers Warn About the Risk of Meningioma?
For much of the time Depo-Provera was on the market, its label warned of many side effects: bone density loss, depression, and irregular menstrual cycles, to name a few. However, the label said nothing about brain tumors.
The drug’s connection to meningioma drew wider attention after a 2024 study reported that prolonged use of injectable medroxyprogesterone acetate carried a substantially higher risk of these tumors. Only in late 2025 did the Food and Drug Administration (FDA) approve a label change adding a meningioma warning in the United States, even after comparable warnings had appeared in other countries.
How to Prove Failure to Warn in a Depo-Provera Lawsuit
To prove a failure to warn claim, you must show that the manufacturer knew, or reasonably should have known, about the meningioma risk and still failed to warn patients and physicians adequately. Building this argument generally calls for several kinds of proof:
- Scientific studies linking long-term Depo-Provera use to meningioma
- The timeline of label changes, showing what the manufacturer disclosed and when
- Internal records and adverse event reports reflecting the company’s awareness of the risk
- Medical records that establish the connection between your Depo-Provera use and meningioma diagnosis
An attorney can weave these pieces of evidence together to craft a compelling claim. They will use the scientific studies and internal records to show what the manufacturer should have disclosed, then connect that lapse to a specific diagnosis through the client’s medical history.
Find Out Where Your Case Stands with Shapiro Legal Group, PLLC
Failure to warn about a dangerous side effect can change the entire course of a person’s life. The attorneys at Shapiro Legal Group, PLLC can help identify what the makers of Depo-Provera knew—and when they knew it. If you used the injection and were later diagnosed with a meningioma, contact our firm to find out where your case stands.